Clinical Trial Update: Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating PF-04691502 in combination with exemestane versus exemestane alone for advanced breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Exemestane (Exemestane)
• PF-04691502

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Phase 2 | Status: WITHDRAWN